Scientific Presentations

Press releases
Corporate presentation
Scientific Presentations
Scientific Publications
Events and webcasts
Stock information
SEC filings
Financial Statements
Regulated information
Voting Rights & Share Capital
ATM Program
General meetings
Governance
The board and committee members
Corporate governance documents
FAQ
IR Inquiry
All 2024 2023 2022 2021
17 May 2023
14:30 E.S.T.

AMELI 01: A Phase I Trial of UCART123v1.2, an Anti CD123 Allogeneic CAR T Cell Product, in Adult Patients with Relapsed or Refractory (R/R) CD123+ Acute Myeloid Leukemia - ASGCT 2023 - Oral Presentation

Download the PDF file
16 Apr 2023
08:00 E.S.T.

Deciphering the benefits of variable delivery routes and molecular armoring to enhance efficacy of MUC1-CAR T-cells in targeting triple-negative breast cancer - AACR 2023 - Poster presentation

Download the PDF file
13 Dec 2022
09:30 E.S.T.

Cellectis Live Webcast Presentation- December 13, 2022

Download the PDF file
12 Dec 2022
18:00 E.S.T.

AMELI-01:Preliminary Results from A Phase I Trial of UCART123v1.2, an Anti-CD123 Allogeneic CAR-T Cell Product, in Adult Patients with Relapsed or Refractory (R/R) CD123+ Acute Myeloid Leukemia- ASH 2022- Oral Presentation

Download the PDF file
10 Dec 2022
18:30 E.S.T.

Preclinical Activity of Allogeneic CS1-Specific CAR T-Cells (UCARTCS1) in Multiple Myeloma - ASH 2022 - Poster Presentation

Download the PDF file
10 Nov 2022
09:00 E.S.T.

TALEN®-edited smart CAR T-cells leverage solid tumor microenvironment for specific and effective immunotherapy - SITC 2022- Poster Presentation

Download the PDF file
10 Nov 2022
09:00 E.S.T.

Multi-armored allogeneic MUC-1 CAR T-cells efficiently control triple negative breast cancer tumor growth- SITC 2022- Poster Presentation

Download the PDF file
26 Oct 2022
09:00 E.S.T.

TALEN®-edited SMART CAR T-cells leverage solid tumor microenvironment for specific and effective immunotherapy- ENA 2022- Poster Presentation

Download the PDF file
13 Oct 2022
09:00 E.S.T.

Non-viral DNA delivery associated to TALEN® gene editing leads to highly efficient correction of sickle cell mutation in long-term repopulating hematopoietic stem cells- ESGCT 2022- Oral Presentation

Download the PDF file
11 Oct 2022
16:27 E.S.T.

Non-viral DNA delivery associated to TALEN® gene editing leads to highly efficient correction of sickle cell mutation in long-term repopulating hematopoietic stem cells- ESGCT 2022- Abstract

Download the PDF file